Recently, Park J. et al. identified three new GBM subtypes—mitotic (characterized by association with the methylated MGMT gene promoter and sensitive to TMZ treatment), intermediate, and invasive subtypes—through the analysis of four large-scale gene expression profiles [13]. The gene discussed is MGMT; the disease is glioblastoma.